TherapeuticsMD, Inc. Applauds Congressional Leadership On Passage Of Drug Quality And Security Act

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company, commented today on yesterday's passage of H.R. 3204, the Drug Quality and Security Act.

Robert Finizio, Chief Executive Officer and Co-founder of TherapeuticsMD, said, "The Drug Quality and Security Act is intended to improve the safety of drugs manufactured by compounding pharmacies in the United States and is a vital step for protecting public health. We applaud the many legislators in both houses of Congress who came together in a strong bipartisan effort to pass this critical legislation.

Help employers find you! Check out all the jobs and post your resume.

Back to news